MPRIP

MPRIP is a multifunctional scaffold protein that spatially targets myosin light chain phosphatase (MLCP) to actomyosin stress fibers, thereby controlling myosin II phosphorylation, contractility, and cytoskeletal dynamics across diverse cell types. Its N-terminal region binds and bundles F-actin (Kd ~0.5 µM), while its C-terminal coiled-coil domain binds the myosin phosphatase targeting subunit MYPT1 and mediates oligomerization; loss of MPRIP displaces MYPT1 from stress fibers and increases myosin light chain phosphorylation, augmenting contractility (PMID:12732640, PMID:16257966, PMID:31347175). MPRIP additionally inactivates RhoA through a GAP-like activity, is phosphorylated by PKG to enhance MLCP function, and is cleaved by caspases during apoptosis to generate a MYPT1-binding fragment that regulates bleb retraction through localized myosin dephosphorylation (PMID:15545284, PMID:23723008, PMID:40344468). In the nucleus, MPRIP binds PIP2, forms phase-separated condensates via its intrinsically disordered region, and recruits Tyr1-phosphorylated RNA Polymerase II to PIP2-containing structures, regulating transcription elongation and RNAPII condensate dynamics (PMID:33918018, PMID:36979361).

1. 2003 High

   Establishing that MPRIP is an F-actin-binding and bundling protein that co-localizes with stress fibers and myosin-II answered the fundamental question of how MPRIP interfaces with the actomyosin cytoskeleton.

   Evidence F-actin co-sedimentation (Kd ~0.5 µM), electron microscopy of bundles, immunoprecipitation, and deletion-mutant imaging in cultured cells

   PMID:12732640

   Open questions at the time

   • Structural basis of actin binding and bundling not resolved
   • Whether bundling activity is physiologically relevant in vivo was untested
2. 2004 High

   Demonstrating that MPRIP directly binds MYPT1, activates MLCP toward myosin substrates, and functions as a RhoA GAP-like regulator established the dual mechanism by which MPRIP promotes myosin dephosphorylation — enhancing phosphatase targeting and reducing upstream RhoA signaling.

   Evidence In vitro GTPase and phosphatase assays, domain-mapping co-IP, siRNA knockdown with phospho-MLC quantification in multiple cell types

   PMID:15469989 PMID:15545284

   Open questions at the time

   • Whether GAP activity and MLCP-targeting function independently or cooperatively in vivo was unresolved
   • Identity of residues mediating RhoA GAP activity not defined
3. 2005 High

   Showing that MPRIP targets MYPT1 to stress fibers in vascular smooth muscle cells, with its loss increasing basal myosin phosphorylation and stress fiber density, confirmed the physiological scaffolding function in a contractile cell type relevant to vascular tone.

   Evidence siRNA knockdown in vascular smooth muscle cells with immunofluorescence localization and phospho-MLC quantification

   PMID:16257966

   Open questions at the time

   • In vivo relevance in intact vasculature or animal models not tested
   • Regulation of MPRIP expression or stability in smooth muscle was unknown
4. 2012 Medium

   Identifying the MPRIP–syntenin-1 complex as a Src-dependent hub for polarized Rac-1 activation extended MPRIP's role beyond myosin phosphatase targeting to spatially regulated actin polymerization at the leading edge and immune synapse.

   Evidence Co-IP with phospho-mutants, siRNA knockdown, GTPase activity assays, and confocal imaging in T cells

   PMID:22349701

   Open questions at the time

   • Whether MPRIP's Rac-1 regulatory role is independent of its MLCP-targeting function was not dissected
   • Single lab finding not independently confirmed
5. 2014 Medium

   Demonstrating PKG-mediated phosphorylation of MPRIP as a mechanism to enhance MPRIP–MYPT1 association and MLCP activity established how the cGMP/NO signaling axis converges on MPRIP to promote smooth muscle relaxation.

   Evidence PKG activation (GSNO/cGMP) with co-IP for MPRIP–MYPT1 binding, siRNA rescue, and phospho-MLC quantification in gastric smooth muscle

   PMID:23723008

   Open questions at the time

   • Specific PKG phosphorylation site(s) on MPRIP not mapped
   • Whether PKG phosphorylation also affects RhoA GAP activity was not tested
6. 2019 Medium

   Revealing that MPRIP depletion in airway smooth muscle increases di-phosphorylated MLC via impaired MLCP–myosin interaction (with ZIPK involvement) extended the scaffolding model to airway contractility and identified a previously unrecognized kinase input.

   Evidence siRNA knockdown, phospho-MLC quantification, co-IP of MLCP–myosin, ZIPK inhibitor, collagen gel contraction assay in human airway smooth muscle cells

   PMID:31347175

   Open questions at the time

   • Mechanism by which ZIPK compensates for MPRIP loss is unclear
   • In vivo airway contractility data not provided
7. 2020 Medium

   Identifying Ermin as an MPRIP partner that cooperates to inactivate RhoA for oligodendrocyte morphogenesis connected MPRIP's cytoskeletal regulatory function to CNS myelination.

   Evidence Co-IP, RhoA activity assay, Ermn knockout mouse with histological, behavioral, and myelin analysis

   PMID:32530539

   Open questions at the time

   • Direct loss of MPRIP in oligodendrocytes or CNS was not tested
   • Whether MPRIP's GAP-like activity or MLCP-targeting underlies the myelination phenotype is undetermined
8. 2021 Medium

   Discovering that MPRIP localizes to the nucleus, binds PIP2, associates with RNAPII/Nuclear Myosin 1, and forms phase-separated condensates via its intrinsically disordered region revealed an unexpected nuclear function beyond cytoskeletal regulation.

   Evidence Subcellular fractionation, super-resolution microscopy, co-IP/mass spectrometry, PIP2 binding assay, live-cell condensate imaging, deletion mutant analysis

   PMID:33918018

   Open questions at the time

   • Functional consequence of nuclear condensates for gene expression not established
   • Mechanism separating cytoplasmic versus nuclear pools of MPRIP unknown
9. 2023 Medium

   Showing that nuclear MPRIP recruits elongating (Tyr1-phosphorylated) RNAPII to PIP2 structures, and that its depletion increases RNAPII initiation condensates, established MPRIP as a regulator of transcription elongation/pause-release through nuclear lipid–actin compartments.

   Evidence siRNA depletion, super-resolution microscopy, co-IP, proximity ligation assay, transcription assays

   PMID:36979361

   Open questions at the time

   • Genome-wide transcriptional targets affected by MPRIP loss not identified
   • Whether F-actin binding and PIP2 binding are independently required for transcription regulation is unresolved
   • Single lab findings require independent confirmation
10. 2025 High

    Demonstrating that caspase cleavage of MPRIP generates a C-terminal fragment that retains MYPT1 binding and promotes localized MLC dephosphorylation at retracting blebs established how apoptotic cells repurpose the MPRIP–MLCP axis for dynamic bleb regulation.

    Evidence In vitro caspase cleavage assay, FRET-based RMLC phosphorylation biosensor, 3D live imaging, co-IP of cleaved fragment with MYPT1/myosin, domain analysis

    PMID:40344468

    Open questions at the time

    • Specific caspase(s) responsible for cleavage in vivo not definitively identified
    • Whether caspase cleavage also affects nuclear MPRIP functions is unexplored

• How MPRIP's cytoplasmic scaffolding of MLCP and its nuclear phase-separation/transcription functions are coordinated, regulated by signaling cues, and partitioned between compartments remains an open question.
• No structural model of MPRIP or its complexes exists
• No MPRIP knockout animal model has been characterized
• Mechanism governing nuclear–cytoplasmic partitioning of MPRIP is unknown
• Genome-wide transcriptional consequences of MPRIP loss are undefined